Skip to content
Home/Companies/Biotech/Exicure

Exicure

Biotech·US·Active·7yr hold
Entry
2019
Hold
7yr
Status
Active

Who owns Exicure?

Exicure is currently owned by Abingworth through Abingworth Bioventures VI (2014 vintage), since 2019.

Hand-verified · updated 2026-06-07

Abingworth
Investor
Abingworth
Abingworth Bioventures VI · 2014 · Life Sciences VC

Key facts

HQUS
SectorBiotech
StatusActive

More from Abingworth Bioventures VI

Other portfolio companies in the same fund.

Verona Pharma
Verona Pharma
Exited 2025
BiotechUK
to
Venatorx Pharmaceuticals
Venatorx Pharmaceuticals
Active
HealthcareUS· 2022
Soleno Therapeutics
Soleno Therapeutics
Exited 2026
BiotechUS· 2018
to
Tizona Therapeutics
Tizona Therapeutics
Active
BiotechUS· 2016
Median Technologies
Active
HealthcareFrance· 2015
Avedro
Exited 2019
MedTechUS· 2014
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Exicure

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Exicure.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue